Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Tesla board members officially settle excessive compensation case for nearly $1 billion
India Delays First Space Docking Test of SpaDeX Satellites Until January 9, Requires ‘Further Validation’
Car maker meets electric vehicle target despite criticising the goal and closing its Luton plant
Johnson: My teenage son has ‘no role’ with Jets
Apple’s market share slides in China as iPhone shipments decline, analyst Kuo says